Comparative Pharmacology
Head-to-head clinical analysis: IBUPROFEN versus TAB PROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPROFEN versus TAB PROFEN.
Ibuprofen vs TAB-PROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor; reduces prostaglandin synthesis.
200-800 mg orally every 6-8 hours; maximum 3200 mg/day.
400-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours; no accumulation with repeated dosing in normal renal function.
The terminal elimination half-life is 2-4 hours in adults with normal renal function. In elderly patients or those with renal impairment, half-life may be prolonged up to 8-12 hours, requiring dose adjustment.
Clinical Note
moderateIbuprofen + Gatifloxacin
"Ibuprofen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateIbuprofen + Rosoxacin
"Ibuprofen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateIbuprofen + Levofloxacin
"Ibuprofen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateIbuprofen + Trovafloxacin
"Ibuprofen may increase the neuroexcitatory activities of Trovafloxacin."
Renal excretion of conjugated metabolites (about 90% as glucuronide and sulfate conjugates, <10% as unchanged drug); minor biliary/fecal elimination (<5%).
Renal excretion of unchanged drug accounts for approximately 70-90% of the administered dose, with the remainder eliminated as glucuronide conjugates in urine. Biliary/fecal elimination is minimal (<5%).
Category D/X
Category C
NSAID
NSAID